search
diabetes patients
Trends
- 1Diabetes study suggests steady blood sugar may carry hidden cost▼Diabetes study finds keeping blood sugar too steady may come at a price
New research into diabetes suggests that keeping blood sugar levels extremely stable may come at a cost, challenging the assumption that tighter control is always better for patients. The findings are drawing attention among clinicians and people managing diabetes, who are weighing what the results could mean for treatment targets and everyday glucose management advice.
- 2Israeli startup DreaMed wins FDA nod for insulin-dosing app▼Israeli startup DreaMed gets FDA approval for app that adjusts insulin doses for Type 2 diabetes
Israeli medtech startup DreaMed Diabetes has received FDA approval for an app that automatically adjusts insulin doses for people with Type 2 diabetes. The clearance lets the company bring its digital insulin-management tool to American patients, extending technology previously aimed at Type 1 diabetes. The news, reported by Calcalist, is being read as a milestone for Israeli digital health firms seeking US market entry.
- 3Israeli startup wins FDA clearance for injection-based diabetes app▼Israeli startup develops injection-based diabetes app, receives FDA clearance
An Israeli startup has received FDA clearance for an app designed to support people who manage diabetes with insulin injections. The digital tool aims to help patients track and manage their injection-based treatment, and its clearance means it can now be marketed in the United States. The news was reported by The Jerusalem Post and highlights Israel's growing health-tech sector.
- 4New insight into how lipodystrophy affects overall health▼New insight into how lipodystrophy can affect overall health
Researchers at Michigan Medicine report new findings on lipodystrophy, a rare disorder in which the body lacks healthy fat tissue, showing how the condition affects far more than fat storage. The work highlights links between abnormal fat metabolism and broader health problems such as diabetes, fatty liver and heart disease, offering a clearer picture of why patients face widespread metabolic complications.
- 5FDA approves Onswik, a once-weekly insulin for type 2 diabetes●The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.